Slides

PAH Highlights from CHEST 2020

Key PAH Abstracts Presented at CHEST 2020

Pozella P et al. UNDERSTANDING THE PSYCHOLOGICAL MINDSET OF PEOPLE WITH PAH. Chest J. 2020. 158; (suppl): A1847. DOI: https://doi.org/10.1016/j.chest.2020.08.1603

Moreland K et al. REASONS FOR REFUSING PARENTERAL THERAPY: A QUALITATIVE STUDY OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION, Chest J. 2020. 158; (suppl): A2274. DOI: http://dx.doi.org/10.1016/j.chest.2020.08.1930

Follman B et al. ECHOCARDIOGRAPHIC RV/PA COUPLING IDENTIFIES RACIAL HEALTH DISPARITIES IN PULMONARY ARTERIAL HYPERTENSION. Chest J. 2020. 158; (suppl): A2249. DOI: http://dx.doi.org/10.1016/j.chest.2020.08.1915

Alturaif N et al. PHYSICIANS ATTITUDES TOWARD ANTICOAGULATION USE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Chest J. 2020. 158; (suppl): A2234 DOI: http://dx.doi.org/10.1016/j.chest.2020.08.1905

Kingrey J et al. INTERIM DATA FROM THE ADAPT REGISTRY: REAL-WORLD TOLERABILITY AND MANAGEMENT OF ADVERSE EVENTS IN PATIENTS RECEIVING ORAL TREPROSTINIL. Chest J. 2020. 158; (suppl): A2169-A2170. DOI: http://dx.doi.org/10.1016/j.chest.2020.08.1864

Hoeper M et al. SWITCHING TO RIOCIGUAT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION NOT AT TREATMENT GOAL WITH PHOSPHODIESTERASE TYPE-5 INHIBITORS: SUBGROUP ANALYSIS RESULTS OF THE REPLACE STUDY. Chest J. 2020. 158; (suppl): A2156- A2159. DOI: http://dx.doi.org/10.1016/j.chest.2020.08.1857

Torbicki A et al. EFFECT OF MACITENTAN ON CARDIAC FUNCTION IN PULMONARY ARTERIAL HYPERTENSION: RESULTS FROM THE REPAIR ECHOCARDIOGRAPHY SUBSTUDY. Chest J. 2020. 158; (suppl): A2224-A2227. DOI: http://dx.doi.org/10.1016/j.chest.2020.08.1899

Ghosh S et al. LONG TERM SURVIVAL AND TRANSPLANT RATES IN PULMONARY ARTERIAL HYPERTENSION PATIENTS TREATED WITH PARENTERAL PROSTACYCLIN THERAPY. Chest J. 2020. 158; (suppl): A2262-A2263. DOI: http://dx.doi.org/10.1016/j.chest.2020.08.1922

Kingrey J et al. INTERIM DATA FROM THE ADAPT REGISTRY: REAL-WORLD TOLERABILITY AND MANAGEMENT OF ADVERSE EVENTS IN PATIENTS RECEIVING ORAL TREPROSTINIL. Chest J. 2020. 158; (suppl): A2169-A2170. DOI: http://dx.doi.org/10.1016/j.chest.2020.08.1864

McConnell J et al. EXPERIENCE WITH MACITENTAN TRIPLE COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION: REAL-WORLD EVIDENCE FROM THE OPUS REGISTRY. Chest J. 2020. 158; (suppl): A2217-A2219. DOI: http://dx.doi.org/10.1016/j.chest.2020.08.1895

Keogh A et al. ACUTE HEMODYNAMIC IMPROVEMENT IN CHRONIC PULMONARY ARTERIAL HYPERTENSION ON DUAL THERAPY FOLLOWING RT234 INHALATION. Chest J. 2020. 158; (suppl): A2162-2163. DOI: http://dx.doi.org/10.1016/j.chest.2020.08.1860

PAH Clinical Trials

https://clinicaltrials.gov/pah

Jointly Provided by

Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

Start date: February 28, 2021
End date: February 28. 2022
NO LONGER AVAILABLE FOR CREDIT
Estimated time to complete: 0.25 hours

Activity Description

Although CHEST 2020 was not a live, in-person meeting, new information and data regarding pulmonary arterial hypertension (PAH) will still be published but will not be easily accessible to the care team involved in the diagnosis and management of patients with this rare disease who need to know and incorporate the latest information into patient care. This CME activity highlights the latest research on PAH to help clinicians keep up to date on the most efficient ways to manage their patients.

Activity Faculty

Richard N Channick, MD
Professor of Medicine
David Geffen School of Medicine at UCLA
Director of the Pulmonary Vascular Disease Program
Ronald Reagan UCLA Medical Center

Target Audience

This activity has been designed to meet the educational needs of physicians caring for individuals with pulmonary arterial hypertension (PAH). Other members of the care team may also participate.

Learning Objectives

After participating in the activity, learners should be better able to:

• Describe the latest research being presented to better manage people with PAH and its clinical relevance

Accreditation and Credit Designation

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

Disclosures are as follows:

Richard N Channick, MD discloses the following financial relationships:
Advisory Board: Actelion, Bayer, United Therapeutics
Consultant: Actelion, Bayer, Gossamer
Promotional Speaker’s Bureau: Actelion, Bayer

Planners for this activity have no relevant financial relationships with any commercial interests.

This activity will review off-label or investigational information.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the post-program assessment. Your certificate can be mailed to you in approximately 30 days.

Hardware/Software Requirements

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Privacy

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm. For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/

Contact

For any questions, please contact: [email protected]

Copyright

© 2021. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Transcripts

PAH Highlights from CHEST 2020